ArticleiScience2026
An explainable machine learning model predicts 30-day readmission after vertebral augmentation.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic vertebral compression fracture (OVCF) patients face high 30-day readmission risks after vertebral augmentation procedures (VAPs). Using electronic health records (EHRs) of 3,947 OVCF patients who underwent VAPs (2019-2024), we developed an interpretable machine learning model to identify readmission predictors. Eight algorithms were evaluated via 10-fold cross-validation, and XGBoost showed the best performance (area under the curve [AUC], sensitivity, specificity, F1 score, and decision curve analysis). SHapley Additive exPlanations (SHAPs) analysis revealed key predictors including frailty, fall history, prolonged hospitalization, comorbidities (pulmonary/kidney disease), advanced age, and hypoalbuminemia. A clinical web application was created for real-time risk stratification, visualizing individualized risk contributions via SHAP to enable proactive interventions and targeted prevention, thereby improving outcomes and reducing healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.